Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease

Movement Disorders

Volumn 28, Issue 10, 2013, Pages 1398-1406

  Quik, Maryka ^a   Mallela, Archana ^a   Ly, Jason ^a   Zhang, Danhui ^a  

^a SRI INTERNATIONAL   (United States)

Author keywords

Dyskinesia; Levodopa; Nicotine; Nicotinic; Nonhuman primate; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CARBIDOPA PLUS LEVODOPA; COTININE; LEVODOPA; NICOTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERANCE; DYSKINESIA; GOLD STANDARD; LEVODOPA INDUCED DYSKINESIA; MALE; MONKEY MODEL; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; TREATMENT DURATION;

DYSKINESIA; LEVODOPA; NICOTINE; NICOTINIC; NONHUMAN PRIMATE; PARKINSON'S DISEASE;

ANIMALS; ANTI-DYSKINESIA AGENTS; ANTIPARKINSON AGENTS; COTININE; DATA INTERPRETATION, STATISTICAL; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; MALE; MPTP POISONING; NICOTINE; NICOTINIC AGONISTS; PARKINSON DISEASE, SECONDARY; SAIMIRI;

EID: 84884712091     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25594     Document Type: Article

References (56)

1. Poewe W, Mahlknecht P, Jankovic J. Emerging therapies for Parkinson's disease. Curr Opin Neurol 2012;25:448-459.
2. Brotchie J, Jenner P. New approaches to therapy. Int Rev Neurobiol 2011;98:123-150.
3. Carta M, Bezard E. Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia. Neuroscience 2011;198:245-251.
4. Fisone G, Bezard E. Molecular mechanisms of l-DOPA-induced dyskinesia. Int Rev Neurobiol 2011;98:95-122.
5. Iravani MM, Jenner P. Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. J Neural Transm 2011;118:1661-1690.
6. Cenci MA, Konradi C. Maladaptive striatal plasticity in l-DOPA-induced dyskinesia. Progr Brain Res 2010;183C:209-233.
7. Prashanth LK, Fox S, Meissner WG. l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment. Int Rev Neurobiol 2011;98:31-54.
8. Rascol O, Lozano A, Stern M, Poewe W. Milestones in Parkinson's disease therapeutics. Mov Disord 2011;26:1072-1082.
9. Quik M, Wonnacott S. α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease. Pharmacol Rev 2011;63:938-966.
10. Huang L, Grady SR, Quik M. Nicotine reduces L-dopa-induced dyskinesias by acting at β 2 nicotinic receptors. J Pharmacol Exp Ther 2011;338:932-941.
11. Bordia T, Campos C, Huang L, Quik M. Continuous and intermittent nicotine treatment reduces L-3, 4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease. J Pharmacol Exp Ther 2008;327:239-247.
12. Quik M, Cox H, Parameswaran N, O'Leary K, Langston JW, Di Monte D. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann Neurol 2007;62:588-596.
13. Bordia T, Campos C, McIntosh JM, Quik M. Nicotinic receptor-mediated reduction in L-dopa-induced dyskinesias may occur via desensitization. J Pharmacol Exp Ther 2010;333:929-938.
14. Quik M, Mallela A, Chin M, McIntosh JM, Perez XA, Bordia T. Nicotine-mediated improvement in l-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function. Neurobiol Dis 2013;50:30-41.
15. Tan LC, Protell PH, Langston JW, Togasaki DM. The hyperkinetic abnormal movements scale: a tool for measuring levodopa-induced abnormal movements in squirrel monkeys. Mov Disord 2002;17:902-909.
16. Matta SG, Balfour DJ, Benowitz NL, et al. Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) 2007;190:269-319.
17. Adell A, Castro E, Celada P, Bortolozzi A, Pazos A, Artigas F. Strategies for producing faster acting antidepressants. Drug Discov Today 2005;10:578-585.
18. Slattery DA, Hudson AL, Nutt DJ. Invited review: the evolution of antidepressant mechanisms. Fundam Clin Pharmacol 2004;18:1-21.
19. Thompson C. Onset of action of antidepressants: results of different analyses. Hum Psychopharmacol 2002;17(suppl 1):S27-S32.
20. Kuhar MJ, Joyce AR. Slow onset of CNS drugs: can changes in protein concentration account for the delay? Trends Pharmacol Sci 2001;22:450-456.
21. Gotti C, Clementi F, Fornari A, et al. Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem Pharmacol 2009;78:703-711.
22. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005;48:3474-3477.
23. Rollema H, Coe JW, Chambers LK, et al. Rationale, pharmacology and clinical efficacy of partial agonists of alpha(4)beta(2) nACh receptors for smoking cessation. Trends Pharmacol Sci 2007;28:316-325.
24. Rollema H, Chambers LK, Coe JW, et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007;52:985-994.
25. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:47-55.
26. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56-63.
27. Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 2006;70:801-805.
28. Bordia T, Hrachova M, Chin M, McIntosh JM, Quik M. Varenicline is a potent partial agonist at alpha6beta2* nicotinic acetylcholine receptors in rat and monkey striatum. J Pharmacol Exp Ther 2012;342:327-334.
29. Huang LZ, Campos C, Ly J, Carroll FI, Quik M. Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in moderately lesioned parkinsonian rats. Neuropharmacology 2011;60:861-868.
30. Mukhin AG, Gundisch D, Horti AG, et al. 5-Iodo-A-85380, an alpha4beta2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol Pharmacol 2000;57:642-649.
31. Kulak JM, Sum J, Musachio JL, McIntosh JM, Quik M. 5-Iodo-A-85380 binds to alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors (nAChRs) as well as alpha4beta2* subtypes. J Neurochem 2002;81:403-406.
32. Toulorge D, Guerreiro S, Hild A, Maskos U, Hirsch EC, Michel PP. Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+. FASEB J 2011;25:2563-2573.
33. Quik M, Perez XA, Bordia T. Nicotine as a potential neuroprotective agent for Parkinson's disease. Mov Disord 2012;27:947-957.
34. Dajas-Bailador F, Wonnacott S. Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol Sci 2004;25:317-324.
35. Mudo G, Belluardo N, Fuxe K. Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms. J Neural Transm 2007;114:135-147.
36. Picciotto MR, Zoli M. Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease. Front Biosci 2008;13:492-504.
37. Ward RJ, Lallemand F, de Witte P, Dexter DT. Neurochemical pathways involved in the protective effects of nicotine and ethanol in preventing the development of Parkinson's disease: Potential targets for the development of new therapeutic agents. Prog Neurobiol 2008;85:135-147.
38. Kawamata J, Shimohama S. Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer's and Parkinson's diseases. J Alzheimers Dis 2011;24(suppl 2):95-109.
39. Shimohama S. Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models. Biol Pharm Bull 2009;32:332-336.
40. Carta M, Carlsson T, Munoz A, Kirik D, Bjorklund A. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Progr Brain Res 2008;172:465-478.
41. Dao JM, McQuown SC, Loughlin SE, Belluzzi JD, Leslie FM. Nicotine alters limbic function in adolescent rat by a 5-HT1A receptor mechanism. Neuropsychopharmacology 2011;36:1319-1331.
42. Fletcher PJ, Le AD, Higgins GA. Serotonin receptors as potential targets for modulation of nicotine use and dependence. Progr Brain Res 2008;172:361-383.
43. Levin ED, Slade S, Johnson M, et al. Ketanserin, a 5-HT2 receptor antagonist, decreases nicotine self-administration in rats. Eur J Pharmacol 2008;600(1-3):93-97.
44. Zaniewska M, McCreary AC, Wydra K, Filip M. Differential effects of serotonin (5-HT)2 receptor-targeting ligands on locomotor responses to nicotine-repeated treatment. Synapse 2010;64:511-519.
45. Zaniewska M, McCreary AC, Filip M. Interactions of serotonin (5-HT)2 receptor-targeting ligands and nicotine: locomotor activity studies in rats. Synapse 2009;63:653-661.
46. Quik M, O'Leary K, Tanner CM. Nicotine and Parkinson's disease: implications for therapy. Mov Disord 2008;23:1641-1652.
47. Ishikawa A, Miyatake T. Effects of smoking in patients with early-onset Parkinson's disease. J Neurol Sci 1993;117(1-2):28-32.
48. Fagerstrom KO, Pomerleau O, Giordani B, Stelson F. Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology (Berl) 1994;116:117-119.
49. Clemens P, Baron JA, Coffey D, Reeves A. The short-term effect of nicotine chewing gum in patients with Parkinson's disease. Psychopharmacology (Berl) 1995;117:253-256.
50. Ebersbach G, Stock M, Muller J, Wenning G, Wissel J, Poewe W. Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration. Mov Disord 1999;14:1011-1013.
51. Kelton MC, Kahn HJ, Conrath CL, Newhouse PA. The effects of nicotine on Parkinson's disease. Brain Cogn 2000;43(1-3):274-282.
52. Vieregge A, Sieberer M, Jacobs H, Hagenah JM, Vieregge P. Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study. Neurology 2001;57:1032-1035.
53. Villafane G, Cesaro P, Rialland A, et al. Chronic high dose transdermal nicotine in Parkinson's disease: an open trial. Eur J Neurol 2007;14:1313-1316.
54. Shoulson I. Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease. Neurology 2006;66:408-410.
55. Lemay S, Chouinard S, Blanchet P, et al. Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:31-39.
56. Kyaw WT, Nagai M, Kaneta M, et al. Effect of nicotine on the pharmacokinetics of levodopa. Clin Neuropharmacol 2013;36:46-51.